Archives
-
TPCA-1 and NF-κB: A Causal Assay Framework
2026-10-01
TPCA-1 is an IKK-2 inhibitor suited to dissecting how NF-κB-driven inflammation connects with tubular apoptosis and autophagy in septic acute kidney injury. This article develops a causal assay framework that extends beyond routine cytokine measurements and distinguishes pathway suppression from nonspecific toxicity.
-
D-N-Acetylgalactosamine: Protocol and QC Guide
2026-09-30
D-N-Acetylgalactosamine (SKU B7904) is a defined amino sugar reagent for glycoprotein characterization, brain heteropolysaccharides analysis, and related glycosylation pathway workflows. It is suitable for water-based or validated DMSO preparations, but should not be selected for ethanol-dependent methods or long-term storage of prepared solutions.
-
Candida krusei Phase-Specific Apoptosis in BMECs
2026-09-30
The reference study shows that the yeast and hypha phases of Candida krusei trigger bovine mammary epithelial cell apoptosis through different routes: predominantly mitochondrial signaling for yeast and death ligand/receptor signaling for hyphae. Its phase-resolved co-culture design provides a useful framework for interpreting TLR, ERK, and JNK pathway involvement in fungal mastitis research.
-
Bazedoxifene: Mechanism and Research Benchmarks
2026-09-29
Bazedoxifene is a selective estrogen receptor modulator with tissue-selective activity relevant to postmenopausal osteoporosis and estrogen receptor signaling pathway research. Its reported bone-protective effects and preclinical antimalarial activity provide distinct research directions, but the antimalarial findings remain experimental.
-
PMS Activates GPR30/PI3K/AKT in Osteoporosis
2026-09-29
The reference study combines network pharmacology, ingredient exposure analysis, zebrafish modeling, and MC3T3-E1 cell experiments to investigate PMS, a three-component combination of psoralen, magnoflorine, and sweroside. Its findings implicate GPR30/PI3K/AKT activation in PMS-associated osteoblastic activity and provide a pharmacological framework for studying combination-based osteoporosis interventions.
-
ARCA EGFP mRNA: Transfection Control Guide
2026-09-28
ARCA EGFP mRNA is an enhanced green fluorescent protein mRNA designed for direct fluorescence-based measurement of delivery and protein expression in mammalian cells. Its ARCA cap, approximately 100-nucleotide poly(A) tail, and defined formulation support reproducible mRNA transfection controls, while product-specific limits should guide interpretation.
-
How the Secretory Translocon Regulates N-Glycosylation
2026-09-28
The study reveals how a CCDC134-bound secretory translocon controls GRP94 glycosylation through coordinated effects on OST-A and OST-B. Its structural and functional findings explain how a nascent protein can remodel its translocation environment to protect normally unused glycosylation sites.
-
Gly-Gly-Phe-Gly (GGFG): Research Linker Guide
2026-09-27
Gly-Gly-Phe-Gly (GGFG) is a short peptide spacer intended for research workflows that join molecules or build peptide-containing materials. The product listing reports its sequence, 336.34 g/mol molecular weight, 98% purity, and handling conditions; it does not establish efficacy in any particular conjugate or disease model.
-
LTI6426 Boosts Panobinostat in Myeloma
2026-09-26
A preclinical study found that the protein disulfide isomerase inhibitor LTI6426 enhanced panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant mouse model. The combination induced an endoplasmic-reticulum stress-associated transcriptional response, highlighting candidate response biomarkers while leaving clinical dosing and safety questions unresolved.
-
3X (DYKDDDDK) Peptide: IP-MS Workflow Guide
2026-09-25
Use the 3X (DYKDDDDK) Peptide to support affinity-based recovery and detection of FLAG-tagged proteins, with practical guidance for co-immunoprecipitation, elution, and assay controls. A published PHD2 interactome study shows how FLAG-based capture can feed discovery proteomics when paired with careful expression controls and follow-up validation.
-
ABT-888 (Veliparib) in DNA Repair Workflows
2026-09-25
Use ABT-888 (Veliparib) to test how PARP1/2 inhibition changes DNA-damage responses, chemotherapy sensitivity, and resistance across cancer models. A practical workflow pairs careful stock handling with genotype-aware dose matrices—and keeps PARP-inhibitor evidence distinct from recent findings on CHK1 inhibition in ovarian cancer.
-
3X FLAG peptide for Protein Assay Workflows
2026-09-24
Use the 3X FLAG peptide to improve capture, competitive elution, and detection workflows for FLAG-tagged proteins—without confusing the free peptide with the genetic tag on your construct. Practical optimization guidance also highlights metal-sensitive assay conditions and connects FLAG-based readouts to cell-cycle research on CDK4 and 4E-BP1.
-
3X (DYKDDDDK) Peptide: Workflows & Troubleshooting
2026-09-24
Learn how to use 3X (DYKDDDDK) Peptide as a competitive reagent for FLAG-tagged protein capture, elution, and assay validation—not as a substitute for encoding a tag in your construct. The workflow also shows how to adapt FLAG-based detection to ER translocon studies while protecting sensitive protein interactions and metal-dependent antibody binding.
-
Poly-GA Links ERK1/2 Activation to Tau Pathology
2026-09-23
A cellular study links C9ORF72-associated poly-Glycine-Alanine to ERK1/2 interaction and hyperphosphorylation, accompanied by increased tau phosphorylation, aggregation, and cell death. Pharmacological blockade with U0126 attenuated these outcomes, identifying MEK–ERK signaling as a candidate mechanistic link that warrants testing beyond cellular models.
-
3X FLAG Peptide: From Tagging to Mechanism
2026-09-23
The 3X (DYKDDDDK) Peptide enables controlled FLAG-protein capture, elution, and detection. This article connects tag chemistry with mechanistic assay design using the FAM46C–Plk4 tumor-suppression study as a model for stronger biochemical conclusions.